https://cd3.be/cd3-raises-70-5-million-euros-for-its-fourth-fund/ 2026-04-28T08:53:54+00:00 http://cd3.be/cdthree/wp-content/uploads/2022/05/CD3-news-general_featured_img-4.jpg https://cd3.be/matthias-versele-joins-the-centre-for-drug-design-discovery-as-director-of-drug-discovery-biology/ 2026-04-28T08:57:38+00:00 http://cd3.be/cdthree/wp-content/uploads/2022/05/CD3-news-general_featured_img-4.jpg https://cd3.be/cd3-and-rega-institute-hunt-for-zika-virus-inhibitors-with-the-support-of-eu/ 2026-04-28T08:57:51+00:00 http://cd3.be/cdthree/wp-content/uploads/2022/05/CD3-news-general_featured_img-4.jpg https://cd3.be/cd3-closes-60-million-euro-fund-to-turn-academic-research-into-new-medicines/ 2026-06-16T15:45:29+00:00 http://cd3.be/cdthree/wp-content/uploads/2026/06/CD3-news-HDC.png https://cd3.be/cd3-announces-investment-in-enedra-therapeutics-to-advance-drug-discovery-programmes-from-its-proprietary-casparov-platform-for-difficult-to-treat-cancers/ 2026-09-10T13:46:33+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Enedra.png https://cd3.be/ku-leuven-joins-endlyz-therapeutics-fight-against-parkinsons-disease/ 2026-09-10T13:47:00+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Endlyz.png https://cd3.be/cd3-and-the-kuleuven-lab-of-cellular-transport-systems-join-forces-with-sandboxaq-to-speed-identification-of-new-therapies-for-the-treatment-of-parkinsons-disease/ 2026-09-10T13:47:35+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Sandbox.png https://cd3.be/janssen-announces-promising-antiviral-activity-against-dengue-in-a-phase-2a-human-challenge-model/ 2026-09-10T13:48:19+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-JnJ.png https://cd3.be/ku-leuven-announces-collaboration-and-license-agreement-with-gilead-sciences-for-the-development-of-new-antivirals-against-the-respiratory-syncytial-virus/ 2026-09-10T13:48:42+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Gilead.png https://cd3.be/biohaven-enters-exclusive-license-and-research-collaboration-agreement-with-ku-leuven-to-advance-first-in-class-trpm3-antagonists-for-the-treatment-of-pain/ 2026-09-10T13:49:11+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Biohaven.png https://cd3.be/ku-leuven-develops-very-potent-antiviral-against-dengue/ 2026-09-10T13:49:36+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-JnJ.png https://cd3.be/cd3-and-vib-enter-into-an-exclusive-license-and-research-collaboration-with-springworks-therapeutics-to-develop-tead-inhibitors-for-addressing-biomarker-defined-cancers/ 2026-09-10T13:50:00+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Springworks.png https://cd3.be/aligos-and-ku-leuven-collaborate-to-develop-a-therapeutic-candidate-targeting-coronavirus/ 2026-09-10T13:50:23+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Aligos.png https://cd3.be/cytura-therapeutics-to-develop-a-new-class-of-drugs-targeting-genomic-instability-in-cancer/ 2026-09-10T13:50:54+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Cytura.png https://cd3.be/cd3-vib-and-beactica-announce-drug-discovery-alliance-targeting-inflammatory-diseases/ 2026-09-10T13:51:16+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Beactica.png https://cd3.be/grunenthal-and-ku-leuven-join-forces-to-develop-an-innovative-non-opioid-pain-treatment/ 2026-09-10T13:51:45+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Grunenthal.png https://cd3.be/vib-cd3-and-galapagos-nv-enter-into-a-license-deal-for-the-development-of-malt1-inhibitors/ 2026-09-10T13:52:11+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Galapagos.png https://cd3.be/rewind-therapeutics-secures-15-2-million-euro-to-develop-novel-remyelination-therapies-for-ms/ 2026-09-10T13:52:33+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-Rewind.png https://cd3.be/hit-discovery-constance-gmbh-a-new-european-hub-for-hts-and-compound-management/ 2026-09-10T13:53:11+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/05/News-HDC.png https://cd3.be/assembly-of-coronavirus-particles-as-a-new-target-for-the-development-of-potent-antiviral-drugs/ 2026-10-19T06:42:28+00:00 http://cd3.be/cdthree/wp-content/uploads/2025/03/Nature-News-2.png https://cd3.be/promising-antiviral-drug-candidate-against-dengue-gets-new-opportunity-for-further-development/ 2026-10-19T10:34:02+00:00 http://cd3.be/cdthree/wp-content/uploads/2026/10/News-item-KUL.png https://cd3.be/substantial-open-philanthropy-funding-to-prepare-against-influenza-pandemics/ 2026-10-19T16:48:48+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/harrold-van-barlingen-in-memoriam/ 2026-10-19T16:50:01+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/official-opening-of-the-belgian-virusbank-platform/ 2026-10-19T16:51:45+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/janssen-announces-novel-dengue-antiviral-demonstrates-efficacy-in-pre-clinical-data-published-in-nature/ 2026-10-19T16:52:06+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/aligos-therapeutics-selects-drug-candidate-alg-097558-a-potent-ritonavir-free-oral-protease-inhibitor-for-the-treatment-and-prevention-of-covid-19/ 2026-10-19T16:52:32+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/a-new-cause-of-parkinsons-disease-unravelled/ 2026-10-19T16:53:10+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png https://cd3.be/fda-approves-new-cancer-drug-associated-with-ku-leuven-discovery/ 2026-10-19T16:53:25+00:00 http://cd3.be/cdthree/wp-content/uploads/2024/05/News-CD3-general.png